XML 51 R39.htm IDEA: XBRL DOCUMENT
v3.21.1

License Agreements (Details) - Nucynta Products - USD ($) $ in Thousands |  | 1 Months Ended
--- | --- | ---
Feb. 13, 2020 | Nov. 30, 2018
Grnenthal |  |
License Agreements [Line Items] |  |
Royalty payment as percentage of annual net sales | 14.00% |
Third Amendment to the Nucynta Commercialization Agreement | Maximum | Sales Royalty Structure 1 |  |
License Agreements [Line Items] |  |
Royalty payment limit between January 1, 2019 and December 31, 2021 |  | $ 210,000
Third Amendment to the Nucynta Commercialization Agreement | Assertio | Sales Royalty Structure 1 |  |
License Agreements [Line Items] |  |
Royalty payment as percentage of annual net sales |  | 65.00%
Royalty payment limit between January 1, 2019 and December 31, 2021 |  | $ 180,000
Third Amendment to the Nucynta Commercialization Agreement | Assertio | Sales Royalty Structure 2 |  |
License Agreements [Line Items] |  |
Royalty payment as percentage of annual net sales |  | 14.00%
Third Amendment to the Nucynta Commercialization Agreement | Assertio | Sales Royalty Structure 3 |  |
License Agreements [Line Items] |  |
Royalty payment as percentage of annual net sales |  | 58.00%
Third Amendment to the Nucynta Commercialization Agreement | Assertio | Sales Royalty Structure 4 |  |
License Agreements [Line Items] |  |
Royalty payment as percentage of annual net sales |  | 20.00%
Third Amendment to the Nucynta Commercialization Agreement | Assertio | Sales Royalty Structure 5 |  |
License Agreements [Line Items] |  |
Royalty payment as percentage of annual net sales |  | 15.00%
Royalty payment limit between January 1, 2019 and December 31, 2021 |  | $ 258,000
Third Amendment to the Nucynta Commercialization Agreement | Assertio | Minimum | Sales Royalty Structure 2 |  |
License Agreements [Line Items] |  |
Royalty payment limit between January 1, 2019 and December 31, 2021 |  | 180
Third Amendment to the Nucynta Commercialization Agreement | Assertio | Minimum | Sales Royalty Structure 3 |  |
License Agreements [Line Items] |  |
Royalty payment limit between January 1, 2019 and December 31, 2021 |  | 210,000
Third Amendment to the Nucynta Commercialization Agreement | Assertio | Minimum | Sales Royalty Structure 5 |  |
License Agreements [Line Items] |  |
Royalty payment limit between January 1, 2019 and December 31, 2021 |  | 233,000
Third Amendment to the Nucynta Commercialization Agreement | Assertio | Maximum | Sales Royalty Structure 3 |  |
License Agreements [Line Items] |  |
Royalty payment limit between January 1, 2019 and December 31, 2021 |  | 233,000
Third Amendment to the Nucynta Commercialization Agreement | Assertio | Maximum | Sales Royalty Structure 5 |  |
License Agreements [Line Items] |  |
Royalty payment limit between January 1, 2019 and December 31, 2021 |  | $ 258,000
Nucynta Purchase Agreement | Grnenthal |  |
License Agreements [Line Items] |  |
Royalty payment as percentage of annual net sales | 14.00% |

X
- Definition Represents the royalty payment as percentage of annual net sales. + References No definition available. + Details
Name: | coll_CollaborativeArrangementRoyaltyPaymentAsPercentageOfAnnualNetSales
Namespace Prefix: | coll_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Royalty Payment Limit + References No definition available. + Details
Name: | coll_CollaborativeArrangementRoyaltyPaymentLimit
Namespace Prefix: | coll_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License Agreements [Line Items] + References No definition available. + Details
Name: | coll_LicenseAgreementsLineItems
Namespace Prefix: | coll_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=coll_NucyntaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=coll_GrnenthalGmbhMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=coll_ThirdAmendmentToCommercializationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=coll_SalesRoyaltyStructure1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=coll_AssertioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=coll_SalesRoyaltyStructure2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=coll_SalesRoyaltyStructure3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=coll_SalesRoyaltyStructure4Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=coll_SalesRoyaltyStructure5Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=coll_AssetPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |